Insmed Inc
INSM194.390USD
+0.700+0.36%
收盘 11/12, 16:00（美东）报价延迟15分钟
41.32B总市值
亏损市盈率 TTM
关于 Insmed Inc 公司
Insmed Incorporated 是一家全球生物制药公司。该公司正在推进一系列已获批准和中后期研究药物以及药物发现。其先进的项目涉及肺部和炎症疾病，包括一种在美国、欧洲和日本获批的治疗慢性、衰弱性肺病的疗法。该公司的临床前研究项目涵盖广泛的技术和模式，包括基因治疗、人工智能驱动的蛋白质工程、蛋白质制造、RNA 末端连接和合成救援。其首款商业产品 ARIKAYCE（阿米卡星脂质体吸入混悬液）用于治疗鸟分枝杆菌复合体 (MAC) 肺病，作为联合抗菌药物方案的一部分，用于治疗治疗选择有限或没有替代治疗方案的成人患者。其产品线包括临床阶段项目、brensocatib、TPIP 和 INS1201 以及临床前研究项目。
Insmed Inc简介
公司代码INSM
公司名称Insmed Inc
上市日期Feb 15, 1991
CEOMr. William H. (Will) Lewis, J.D.
员工数量1271
证券类型Ordinary Share
年结日Feb 15
公司地址700 Us Highway 202/206
城市BRIDGEWATER
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编08807
电话19089779900
网址https://insmed.com/
公司代码INSM
上市日期Feb 15, 1991
CEOMr. William H. (Will) Lewis, J.D.
Insmed Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
402.00K
-2.59%
Dr. Melvin A. Sharoky, M.D.
Dr. Melvin A. Sharoky, M.D.
Independent Director
Independent Director
308.40K
-3.70%
Dr. Clarissa Desjardins, Ph.D.
Dr. Clarissa Desjardins, Ph.D.
Independent Director
Independent Director
53.84K
+10.37%
Mr. David R. Brennan
Mr. David R. Brennan
Lead Independent Director
Lead Independent Director
53.77K
-52.74%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
50.16K
+11.22%
Mr. Roger Adsett
Mr. Roger Adsett
Chief Operating Officer
Chief Operating Officer
25.55K
-49.45%
Dr. Martina Flammer, M.D.
Dr. Martina Flammer, M.D.
Chief Medical Officer
Chief Medical Officer
4.27K
-66.30%
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Chief Financial Officer
Chief Financial Officer
239.00
-98.89%
Ms. Elizabeth Mckee Anderson
Ms. Elizabeth Mckee Anderson
Independent Director
Independent Director
--
--
Ms. S. Nicole Schaeffer
Ms. S. Nicole Schaeffer
Chief People Strategy Officer
Chief People Strategy Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
402.00K
-2.59%
Dr. Melvin A. Sharoky, M.D.
Dr. Melvin A. Sharoky, M.D.
Independent Director
Independent Director
308.40K
-3.70%
Dr. Clarissa Desjardins, Ph.D.
Dr. Clarissa Desjardins, Ph.D.
Independent Director
Independent Director
53.84K
+10.37%
Mr. David R. Brennan
Mr. David R. Brennan
Lead Independent Director
Lead Independent Director
53.77K
-52.74%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
50.16K
+11.22%
Mr. Roger Adsett
Mr. Roger Adsett
Chief Operating Officer
Chief Operating Officer
25.55K
-49.45%
收入明细
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
暂无数据
地区USD
名称
营收
占比
US
68.68M
0.00%
Japan
30.67M
0.00%
Europe and rest of worldld
8.06M
0.00%
业务
地区
暂无数据
股东统计
更新时间: 11月8日 周六
更新时间: 11月8日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.33%
JP Morgan Asset Management
9.08%
Darwin Global Management Ltd
9.07%
T. Rowe Price Associates, Inc.
5.19%
BlackRock Institutional Trust Company, N.A.
4.22%
其他
63.12%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.33%
JP Morgan Asset Management
9.08%
Darwin Global Management Ltd
9.07%
T. Rowe Price Associates, Inc.
5.19%
BlackRock Institutional Trust Company, N.A.
4.22%
其他
63.12%
股东类型
持股股东
占比
Investment Advisor
50.22%
Hedge Fund
26.60%
Investment Advisor/Hedge Fund
21.62%
Research Firm
3.02%
Bank and Trust
1.53%
Family Office
1.08%
Sovereign Wealth Fund
0.91%
Pension Fund
0.86%
Individual Investor
0.66%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
895
217.27M
101.89%
+3.61M
2025Q2
807
207.14M
108.81%
-3.07M
2025Q1
804
211.64M
111.66%
-239.74K
2024Q4
767
205.04M
113.32%
-2.57M
2024Q3
712
200.94M
112.58%
+1.71M
2024Q2
657
186.57M
112.00%
+21.58M
2024Q1
564
156.59M
105.42%
-6.86M
2023Q4
544
155.47M
105.16%
-6.81M
2023Q3
515
153.95M
107.69%
-8.46M
2023Q2
506
152.37M
106.87%
-10.75M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
17.60M
8.33%
-627.46K
-3.44%
Jun 30, 2025
JP Morgan Asset Management
12.98M
6.14%
+7.57M
+140.01%
Jun 30, 2025
Darwin Global Management Ltd
19.34M
9.15%
+3.95M
+25.63%
Jun 30, 2025
T. Rowe Price Associates, Inc.
11.08M
5.24%
-1.69M
-13.21%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.99M
4.26%
-4.01M
-30.83%
Jun 30, 2025
Baker Bros. Advisors LP
7.71M
3.65%
+2.33M
+43.35%
Jun 30, 2025
Capital International Investors
7.48M
3.54%
+280.37K
+3.89%
Jun 30, 2025
Capital World Investors
7.68M
3.63%
+11.60K
+0.15%
Sep 30, 2025
Fidelity Management & Research Company LLC
5.05M
2.39%
+1.71M
+51.07%
Jun 30, 2025
State Street Investment Management (US)
4.28M
2.02%
-1.47M
-25.57%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月6日 周四
更新时间: 11月6日 周四
机构名称
占比
Invesco Dorsey Wright Healthcare Momentum ETF
4.62%
Franklin Genomic Advancements ETF
4.55%
VanEck Biotech ETF
4.43%
ProShares Ultra Nasdaq Biotechnology
3.14%
Invesco Nasdaq Biotechnology ETF
3.08%
First Trust Health Care Alphadex Fund
3.03%
iShares Biotechnology ETF
2.82%
Virtus LifeSci Biotech Products ETF
2.48%
Goldman Sachs Hedge Industry VIP ETF
2.32%
Pinnacle Focused Opportunities ETF
2.12%
查看更多
Invesco Dorsey Wright Healthcare Momentum ETF
占比4.62%
Franklin Genomic Advancements ETF
占比4.55%
VanEck Biotech ETF
占比4.43%
ProShares Ultra Nasdaq Biotechnology
占比3.14%
Invesco Nasdaq Biotechnology ETF
占比3.08%
First Trust Health Care Alphadex Fund
占比3.03%
iShares Biotechnology ETF
占比2.82%
Virtus LifeSci Biotech Products ETF
占比2.48%
Goldman Sachs Hedge Industry VIP ETF
占比2.32%
Pinnacle Focused Opportunities ETF
占比2.12%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
